Visiting from the United States? GLPInfo has a North American edition with US channels and dollar prices: open the US edition. Canada follows in a later release.
Research → decisions → accessEvidence checked 13 Sep 2026
Follow the science. See what comes next.
A clearer view of the milestones shaping peptide and GLP-1 medicines in the UK, US and EU: confirmed decisions, company targets and clearly labelled estimates, each with its source. What we track · How estimates are made.
Orforglipron
Eli Lilly · GLP-1 receptor agonist · Small molecule (non-peptide)
Confirmed eventCompany targetRegulator targetEditorial estimateTiming unknown or undatedSafety update
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Confirmed · 1 Apr 2026United States
FDA approves Foundayo (orforglipron) for chronic weight management
FDA approved Foundayo, a once-daily oral non-peptide GLP-1 receptor agonist, for adults with obesity, or overweight with a weight-related condition, alongside diet and physical activity.
Why it matters. The first oral small-molecule GLP-1 medicine approved in the US. UK and EU status are separate records and are verified independently.
Event
Approval
Indication
Chronic weight management (Obesity, or overweight with at least one weight-related condition, alongside diet and physical activity)
FDA approved Foundayo, a once-daily oral non-peptide GLP-1 receptor agonist, for adults with obesity, or overweight with a weight-related condition, alongside diet and physical activity.
Why it matters: The first oral small-molecule GLP-1 medicine approved in the US. UK and EU status are separate records and are verified independently.
No verified events recorded yet. Regulator: EMA / European Commission.
This list is the complete, accessible view of the tracker; the board above draws from exactly the same records. Every entry is labelled Confirmed (official record), Company target (a dated sponsor statement), Regulator target (an official decision date, not a guarantee), GLPInfo estimate (an editorial range with assumptions) or Timing unknown. An approval is never inferred from a target date passing.